Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV

Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on...
February 15, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica

VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
September 24, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
September 17, 2021 13:14 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
September 17, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"

Registration for the September 21, 2021 event now open VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
September 13, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

Establishes leadership position in manufacturing and commercialization of rare cannabinoidsPositions InMed within large and growing consumer health and wellness cannabinoid marketsTransitions InMed...
June 29, 2021 07:00 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
June 17, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

5 g/L cannabinoid yield significantly exceeds reported industry yieldsSignificantly reduces the overall cost of rare cannabinoid manufacturingContinued advancement to GMP-ready large-scale batch...
April 26, 2021 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based...